EMEA-002197-PIP01-17

Key facts

Invented name
Active substance
Soluble human T cell receptor (TCR) directed against the glycoprotein 100 (gp100) melanoma antigen, linked to the single-chain variable fragment (ScFv) domain of the anti-cluster of differentiation 3 (CD3) antibody
Therapeutic area
Oncology
Decision number
EMEA-002197-PIP01-17
PIP number
EMEA-002197-PIP01-17
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of ocular melanoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Immunocore Ltd
Tel. +1 2153139618
E-mail: Chris.Coughlin@immunocore.com
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating